reglab/housing_qa huggingface dataset:
CA Health & Safety Code § 125205 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 2 - Genetic Disease Services|ARTICLE 2 - Long-Term Care for Degenerative Genetic Disease|Section 125205.

125205.  The department and the State Department of Social Services shall, after consultation with the Genetically Handicapped Persons Program of the department and consumer organizations representing persons with chronic and degenerative conditions, as defined in Section 125210, compile a list of long-term care resources that serve adults with chronic and degenerative conditions, as defined. The list of resources shall include those that have already been identified by the Genetically Handicapped Persons Program as serving persons with Huntington’s disease, Joseph’s disease, and Friedrich’s ataxia, and shall include those that have already been identified by consumer organizations representing persons with chronic and degenerative conditions. The list of resources shall include, but not be limited to, the following:(a)  Public and private skilled nursing facilities and intermediate care facilities.(b)  Public and private community residential care facilities.(c)  Public and private out-of-home long-term care resources such as day activity programs, and in-home support service programs. Nothing in this section shall require the State Department of Health Care Services to undertake a survey of long-term care facilities or programs in the state for the purposes of carrying out the requirements of this section.The information shall be made available to the public, upon request, through the Genetically Handicapped Persons Program of the department.(Amended by Stats. 2012, Ch. 23, Sec. 38. (AB 1467) Effective June 27, 2012.)
CA Health & Safety Code § 125210 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 2 - Genetic Disease Services|ARTICLE 2 - Long-Term Care for Degenerative Genetic Disease|Section 125210.

125210.  For the purposes of this article, chronic and degenerative diseases shall include those conditions that are neurological and neuromuscular in origin, including such disorders as Huntington’s disease, Friedrich’s ataxia, Joseph’s disease, and other disorders that are determined by the department to be similar in origin and clinical manifestation to the named disorders, and that affect adults.(Added by Stats. 1995, Ch. 415, Sec. 8. Effective January 1, 1996.)
CA Health & Safety Code § 125215 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 2 - Genetic Disease Services|ARTICLE 2 - Long-Term Care for Degenerative Genetic Disease|Section 125215.

125215.  The department and the State Department of Social Services shall review regulations that currently provide disincentives to providers of in-home and out-of-home long-term care resources, as defined in Section 125205, to accept and serve persons with chronic and degenerative disorders. The review shall be conducted with assistance and input from the Genetically Handicapped Persons Program of the department. These departments shall provide a list of those regulations to the Legislature by September 1, 1982. The regulations subject to review shall be those regulations that do the following:(a)  Affect the admission of patients to state-licensed skilled nursing facilities, intermediate care facilities, and community residential care facilities.(b)  Affect the staffing ratios necessary to care for persons with chronic and degenerative conditions, as defined, within those facilities.(c)  Affect the likelihood of facilities, or of day care programs and in-home support service programs, to refuse the admission of persons with chronic and degenerative conditions, solely on the basis of anticipated jeopardy to their licensing, or on the basis of anticipated liability to the facilities arising from instances where a person’s degenerative condition, by its own clinical merits, results in medical complications that are, in fact, entirely unrelated to the quality of care provided by the facility or program.(Amended by Stats. 2012, Ch. 23, Sec. 39. (AB 1467) Effective June 27, 2012.)
CA Health & Safety Code § 125220 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 2 - Genetic Disease Services|ARTICLE 2 - Long-Term Care for Degenerative Genetic Disease|Section 125220.

125220.  The actions undertaken pursuant to this article shall not impose additional state obligations or expenditures for the care of persons with chronic and degenerative conditions, as defined by this article, unless the Legislature enacts a statute specifically appropriating money for the additional obligations or expenditures.(Added by Stats. 1995, Ch. 415, Sec. 8. Effective January 1, 1996.)
CA Health & Safety Code § 125225 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 2 - Genetic Disease Services|ARTICLE 3 - Huntington s Disease Research and Workshop Grants|Section 125225.

125225.  The Legislature hereby finds and declares that:(a)  Huntington’s disease is a chronic progressive inherited disorder of the central nervous system. (b)  The constellation of mental and physical symptoms, the insidious onset of the disorder, and the torment of those at-risk, waiting throughout their lives to learn if they have been spared, conspire to make “Huntington’s disease one of the most diabolical diseases known to man.” Each child of a patient with Huntington’s disease has a 50/50 chance of getting the disease. (c)  Males, females, and all ethnic groups may be affected and there is no effective treatment or cure. Because so little is known about the disease, many people are misdiagnosed and mistreated. (d)  The suicide rate among Huntington’s disease patients is estimated to be seven times the national rate. (e)  The advancement of scientific knowledge about Huntington’s disease, that, because of its extraordinary range of symptoms, serves as an excellent prototype for other major chronic genetic, neurologic, and psychiatric illnesses and diseases of aging, such as epilepsy, muscular dystrophy, and Parkinson’s disease, will reveal fundamental scientific information that may lead to treatment, prevention, and ultimately a cure for an array of inherited disorders that affect millions. (Added by Stats. 1995, Ch. 415, Sec. 8. Effective January 1, 1996.)
CA Health & Safety Code § 125230 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 2 - Genetic Disease Services|ARTICLE 3 - Huntington s Disease Research and Workshop Grants|Section 125230.

125230.  The director may establish any rules or criteria for grants under this article as the director deems necessary.(Added by Stats. 1995, Ch. 415, Sec. 8. Effective January 1, 1996.)
CA Health & Safety Code § 125235 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 2 - Genetic Disease Services|ARTICLE 3 - Huntington s Disease Research and Workshop Grants|Section 125235.

125235.  There is hereby created a Scientific Advisory Review Committee. The membership of the committee shall be composed of 11 members who shall be representatives from each of the following:(a)  Two from the University of California. (b)  One from Stanford University. (c)  One from the California Institute of Technology. (d)  One from the Hereditary Disease Foundation. (e)  One from the City of Hope. (f)  One from the Health and Welfare Agency appointed by the Secretary of the Health and Welfare Agency. (g)  One appointed by the Speaker of the Assembly. (h)  One appointed by the President pro Tempore of the California Senate. (i)  One from the National Huntington’s Disease Association. (j)  One from the Committee to Combat Huntington’s Disease. Except as otherwise provided in this section, members of the committee shall be appointed by the director, who shall make the appointments based upon recommendations from the entity or organization represented.The members of the committee shall serve at the pleasure of the appointing power. The members of the committee shall serve without compensation, but shall be reimbursed for necessary and travel expenses incurred in the performance of the duties on the committee.The Scientific Advisory Review Committee is hereby abolished one year after the grants under this article have been made by the director.(Added by Stats. 1995, Ch. 415, Sec. 8. Effective January 1, 1996.)
CA Health & Safety Code § 125240 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 2 - Genetic Disease Services|ARTICLE 3 - Huntington s Disease Research and Workshop Grants|Section 125240.

125240.  Pursuant to the rules or criteria as the director may deem necessary, the Scientific Advisory Review Committee shall review and recommend approval of grant applications and monitor programs receiving grants under this article.(Added by Stats. 1995, Ch. 415, Sec. 8. Effective January 1, 1996.)
CA Health & Safety Code § 125245 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 2 - Genetic Disease Services|ARTICLE 3 - Huntington s Disease Research and Workshop Grants|Section 125245.

125245.  The director may make grants as follows:(a)  Individual research grants to scientists and facilities residing in this state that have research experience with basic and clinical investigations on Huntington’s disease and related disorders. Individual research grants shall not exceed twenty thousand dollars ($20,000). (b)  Interdisciplinary workshop grants to scientists and facilities for the purposes of facilitating interchange among an interdisciplinary group of investigators regarding problems in the treatment and care of patients as well as basic research, all of which may be applicable to a variety of genetic or neuro-degenerative disorders in addition to Huntington’s disease. Individual workshop grants shall not exceed twelve thousand five hundred dollars ($12,500). (Added by Stats. 1995, Ch. 415, Sec. 8. Effective January 1, 1996.)
CA Health & Safety Code § 125250 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 2 - Genetic Disease Services|ARTICLE 3 - Huntington s Disease Research and Workshop Grants|Section 125250.

125250.  Not more than 10 percent of any money appropriated for purposes of this article shall be utilized for the administration of this article.(Added by Stats. 1995, Ch. 415, Sec. 8. Effective January 1, 1996.)
CA Health & Safety Code § 125275 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 2 - Genetic Disease Services|ARTICLE 4 - Alzheimer s Disease|Section 125275.

125275.  (a)  The Legislature finds that Alzheimer’s disease, a devastating disease which destroys certain vital cells of the brain, affects more than 1,500,000 Americans. The Legislature also finds that Alzheimer’s disease and related disorders are responsible for 50 percent of all nursing home admissions and Alzheimer’s disease is the fourth leading cause of death in adults. The Legislature recognizes that the disease has serious emotional, financial, and social consequences for its victims and their families. (b)  The Legislature recognizes that the cause of Alzheimer’s disease is presently unknown, and there is no established treatment which can cure, reverse, or stop the progression of Alzheimer’s disease. The Legislature also recognizes that research is the only hope for victims and families. The Legislature finds that existing diagnostic and treatment centers have improved the quality of care available to the victims of Alzheimer’s disease and increased knowledge with respect to Alzheimer’s disease and related disorders. These centers provide clinical opportunities for research and facilitate the collection of essential data regarding Alzheimer’s disease and related disorders, while at the same time providing valuable services such as information and referral, counseling, and training to victims and their families. It is the intent of the Legislature, in enacting this article, to encourage the establishment of geographically dispersed diagnostic and treatment centers for Alzheimer’s disease within every postsecondary higher educational institution with a medical center, and to encourage research to discover the cause of, and a cure for, Alzheimer’s disease. (c)  The functions of the diagnostic and treatment centers shall be designed to serve all of the following purposes: (1)  To provide diagnostic and treatment services and improve the quality of care to victims of Alzheimer’s disease. (2)  To increase research by faculty and students in discovering the cause of, and a cure for, Alzheimer’s disease. (3)  To provide training, monitoring, consultation, and continuing education to the families of those who are affected by Alzheimer’s disease. (4)  To increase the training of health care professionals with respect to Alzheimer’s disease and other acquired brain impairments to the extent that the centers have the requisite expertise. (d)  The diagnostic and treatment centers may collaborate with the Statewide Resources Consultant designated pursuant to Section 4364 of the Welfare and Institutions Code, to the extent that the centers deem necessary in order to fulfill the functions set forth in subdivision (c). (Added by renumbering Section 412 (as amended by Stats. 1995, Ch. 551) by Stats. 1996, Ch. 1023, Sec. 134. Effective September 29, 1996.)
CA Health & Safety Code § 125280 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 2 - Genetic Disease Services|ARTICLE 4 - Alzheimer s Disease|Section 125280.

125280.  (a)  Any postsecondary higher educational institution with a medical center may establish diagnostic and treatment centers for Alzheimer’s disease subject to the department’s grants review process. (b)  The department shall administer grants to postsecondary higher educational institutions that establish diagnostic and treatment centers pursuant to subdivision (a). (c)  Funds appropriated for the purposes of this article by the Statutes of 1987 shall first be used to maintain and enhance, as determined by the department, existing centers and to prevent program cutbacks under subdivision (b). (d)  Alzheimer’s disease grants for the purpose of establishing a diagnostic and treatment center shall be used only for the purposes of this article, including, but not limited to, all of the following: (1)  Salary and benefits for faculty, residents, fellows, and staff of the diagnostic and treatment center. (2)  Costs of supplies and equipment. (3)  Research grants for faculty research to discover the cause of, and a cure for, Alzheimer’s disease. (4)  Research grants for students, residents, and fellows. (5)  General administrative costs of up to 8 percent of the total grant. (e)  The department shall establish criteria for requests for Alzheimer’s disease diagnostic and treatment center grants and Alzheimer’s disease research grants, and for program evaluation. (f)  No grant awarded pursuant to this article shall be approved for any amount that exceeds 25 percent of the total amount of funds appropriated for this purpose in the 1987–88 Regular Session of the Legislature. (g)  The department shall administer a grant program for the purpose of research into the causes, treatment, cure, strategies for coping with, prevention, incidence, and prevalence of Alzheimer’s disease and related disorders. Priority shall be given to grant applications for feasibility studies, startup grants, and matching funds for federal and privately funded research grants. Consideration shall be given to proposals that link service delivery and collect data relative to patient care and the delivery of social services. This research may include, but is not limited to, examinations and recommendations for the improvement of the family, community-based and health care support systems available to Alzheimer’s disease victims, and their caregivers. (h)  Upon request, the department shall make available to the Legislature information regarding the progress of the grant programs established pursuant to this article. (i)  The department shall reduce any grant pursuant to this article by the amount of any federal funds available for the same purposes to the same grantee. (Added by Stats. 1995, Ch. 415, Sec. 8. Effective January 1, 1996.)
CA Health & Safety Code § 125281 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 2 - Genetic Disease Services|ARTICLE 4 - Alzheimer s Disease|Section 125281.

125281.  From funds appropriated to the department in the Budget Act of 2016 for these purposes, the department shall allocate funds to the diagnostic and treatment centers for Alzheimer’s disease established pursuant to Section 125280 to be used for all of the following purposes:(a) To determine the standard of care in early and accurate diagnosis drawing on peer-reviewed evidence, best practices, Medicare and Medicaid policy and reimbursement, and experience working with patients seeking services at a center.(b) To conduct targeted outreach to health professionals through medical school instruction, hospital grant rounds, continuing education, community education, and free online resources.(c) To provide low-cost, accessible detection and diagnosis tools that the center shall make available via open source portals of the postsecondary higher educational institution that established the center. Furthermore, the department shall post these tools on its Internet Web site to serve as a resource for the state.(d) To endorse and disseminate low-cost, accessible detection and diagnosis tools for broad use by health professionals practicing in a variety of settings.(e) To address unique health disparities that exist within diverse populations, with special focus and attention on reaching African Americans, Latinos, and women.(f) To evaluate the educational effectiveness and measure the impact of these efforts, including pretests and posttests for health professionals, metrics, and documented practice change.(Added by Stats. 2016, Ch. 30, Sec. 8. (SB 833) Effective June 27, 2016.)
CA Health & Safety Code § 125283 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 2 - Genetic Disease Services|ARTICLE 4 - Alzheimer s Disease|Section 125283.

125283.  (a) The Center for Healthy Communities, within the State Department of Public Health, shall, on or before January 1, 2021, update the 2009 Alzheimer’s Disease Facts and Figures in California: Current Status and Future Projections to quantify the burden of Alzheimer’s disease on at-risk and underrepresented populations, including African Americans, Asian-Pacific Islanders, Latinos, Hispanics, and women.(b) This section shall remain in effect only until January 1, 2025, and as of that date is repealed.(Added by Stats. 2018, Ch. 737, Sec. 1. (SB 1292) Effective January 1, 2019. Repealed as of January 1, 2025, by its own provisions.)
CA Health & Safety Code § 125285 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 2 - Genetic Disease Services|ARTICLE 4 - Alzheimer s Disease|Section 125285.

125285.  The department shall provide public and professional education on Alzheimer’s disease to educate consumers, caregivers, and health care providers, and to increase public awareness. If the department determines that contracts are required to implement this section, the department may award these contracts on a sole source basis. The contracts shall not be subject to Part 2 (commencing with Section 10100) of Division 2 of the Public Contract Code. Notwithstanding any other provision of law, the balance of funds appropriated pursuant to the Budget Act of 2000 for Alzheimer’s disease education shall be available for encumbrance and expenditure until June 30, 2003.(Added by Stats. 2000, Ch. 93, Sec. 35. Effective July 7, 2000.)
CA Health & Safety Code § 125286.10 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 2 - Genetic Disease Services|ARTICLE 5 - Standards of Service for Providers of Blood Clotting Products for Home Use Act|Section 125286.10.

125286.10.  This article shall be known, and may be cited, as the Standards of Service for Providers of Blood Clotting Products for Home Use Act.(Added by Stats. 2012, Ch. 75, Sec. 1. (AB 389) Effective January 1, 2013.)